{
    "clinical_study": {
        "@rank": "40102", 
        "arm_group": [
            {
                "arm_group_label": "hGH:12months treatment", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "hGH: 6 month un-treatment + 6 month treatment", 
                "arm_group_type": "Active Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "This trial is conducted in Asia. The aim of this trial is to evaluate the efficacy and\n      safety of recombinant human growth hormone (hGH) in subjects with idiopathic short stature\n      in Korea."
        }, 
        "brief_title": "Efficacy and Safety of Recombinant Human Growth Hormone on Height Velocity in Subjects With Idiopathic Short Stature", 
        "completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Growth Disorder", 
            "Idiopathic Short Stature"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Dwarfism", 
                "Growth Disorders"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Informed consent obtained from subject's parents or legally acceptable representative\n             before any trial-related activities. (Trial-related activities are any procedure that\n             would not have been performed during normal management of the subject.)\n\n          -  Pre-pubertal status (males aged from 4 to 11 [both inclusive], females aged from 4 to\n             9 [both inclusive]): an absence of breast development in females (Tanner 1 only) and\n             testicular volume below 4 mL in males\n\n          -  Growth hormone level above 10 ng/mL following a stimulation test (test result within\n             6 months from screening can be used)\n\n          -  Height below 3 percentile\n\n          -  Bone age below or equal to 12 year\n\n          -  Epiphyses confirmed as open in patients at least 10 years or more of age\n\n        Exclusion Criteria:\n\n          -  Known presence of one or more pituitary hormone deficiencies (ACTH\n             (adrenocorticotropic hormone), ADH (antidiuretic hormone), FSH (follicle-stimulating\n             hormone), LH (luteinising hormone), TSH (thyroid-stimulating hormone))\n\n          -  Known primary hypothyroidism, adrenal insufficiency or hypogonadism (treated or\n             untreated)\n\n          -  Specific types of growth failure including, but not limited to, known chromosomal\n             abnormalities associated with growth failure and altered sensitivity to growth\n             hormone\n\n          -  Bone age is advanced over chronological age more than 3 years\n\n          -  Active malignancy, CNS (central nervous system) trauma, active chemotherapy or\n             radiation therapy for neoplasia\n\n          -  Prior history of intracranial hypertension\n\n          -  Hypertrophic cardiomyopathy"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "11 Years", 
            "minimum_age": "4 Years"
        }, 
        "enrollment": {
            "#text": "54", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 24, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01778023", 
            "org_study_id": "GH-3899", 
            "secondary_id": "U1111-1125-4790"
        }, 
        "intervention": {
            "arm_group_label": [
                "hGH:12months treatment", 
                "hGH: 6 month un-treatment + 6 month treatment"
            ], 
            "description": "A weekly dosage of 0.469 mg of somatropin per kg of body weight per week will be injected subcutaneously (under the skin) in the evening in 7 days per week.", 
            "intervention_name": "somatropin", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "February 5, 2014", 
        "link": {
            "description": "Clinical Trials at Novo Nordisk", 
            "url": "http://novonordisk-trials.com"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of", 
                    "zip": "138-736"
                }
            }
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "2", 
        "official_title": "A 12-month, Open-labelled, Randomised, Parallel-group, Multi-centre, Interventional Trial to Evaluate the Efficacy and Safety of Recombinant Human Growth Hormone (hGH) (Norditropin\u00ae Nordilet\u00ae) Therapy on Height Velocity (Ht-V) in Patients With Idiopathic Short Stature in Korea", 
        "overall_official": {
            "affiliation": "Novo Nordisk Pharma Ltd.", 
            "last_name": "Global Clinical Registry (GCR, 1452)", 
            "role": "Study Director"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "South Korea: Korea Food and Drug Administration (KFDA)", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Change in height velocity (Ht-V)", 
            "safety_issue": "No", 
            "time_frame": "From day 0 to the end of treatment (month 6)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01778023"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Change in Ht-SDS (height standard deviation score)", 
                "safety_issue": "No", 
                "time_frame": "From day 0 to the end of treatment (month 6)"
            }, 
            {
                "measure": "Change in IGF related factors: IGF-I (insulin-like growth factor-I)", 
                "safety_issue": "No", 
                "time_frame": "From day 0 to the end of treatment (month 6)"
            }, 
            {
                "measure": "Change in IGF related factors: IGFBP-3 (insulin-like growth factor binding protein-3)", 
                "safety_issue": "No", 
                "time_frame": "From day 0 to the end of treatment (month 6)"
            }, 
            {
                "measure": "Change for bone age", 
                "safety_issue": "No", 
                "time_frame": "From day 0 to the end of treatment (month 6)"
            }, 
            {
                "measure": "Occurrence of Adverse events", 
                "safety_issue": "No", 
                "time_frame": "From day 0 through month 6"
            }, 
            {
                "measure": "Ht-V (height velocity)", 
                "safety_issue": "No", 
                "time_frame": "At the first 6 months and the last 6 months of group A"
            }
        ], 
        "source": "Novo Nordisk A/S", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novo Nordisk A/S", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}